Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 10/20 | 0.56 |
| ▸ | CASP7 | P55210 | 6/20 | 0.52 |
| ▸ | CASP1 | P29466 | 6/20 | 0.52 |
| ▸ | CASP9 | P55211 | 4/20 | 0.52 |
| ▸ | CASP4 | P49662 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 2/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.49 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CASP5 | P51878 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713780 | 1.00 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2043662 | 0.97 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL4952116 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL15939366 | 0.90 | CASP3 (0.64) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL24213871 | 0.90 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP6 | |
| SCHEMBL17494194 | 0.90 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP6 | |
| SCHEMBL14646635 | 0.90 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP6 | |
| SCHEMBL2034510 | 0.90 | CASP1 (0.67) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2043035 | 0.90 | CASP1 (0.67) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL3692630 | 0.88 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250320284-A1 | Novel Molecules for Therapy and Diagnosis | AC IMMUNE SA (CH) | 2025-10-16 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12247080-B2 | Anti-DR5 antibodies and methods of use thereof | GENMAB B.V. (NL) | 2025-03-11 | — | — | US | disclosed |
| EP-4467648-A2 | ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF | Genmab B.V. (NL) | 2024-11-27 | — | — | EP | disclosed |
| EP-4464333-A2 | ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | Genmab B.V. (NL) | 2024-11-20 | — | — | EP | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| WO-2009000538-A1 | TRIMERIC DEATH LIGANDS WITH ENHANCED ACTIVITY (TENASCIN) | APOGENIX GMBH (DE) | 2008-12-31 | — | — | WO | disclosed |
| EP-2009022-A1 | Trimeric death ligands with enhanced activity (tenascin) | Apogenix GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008012563-A2 | USE OF CDK INHIBITORS FOR THE TREATMENT OF GRANULOCYTE MEDIATED DISORDERS | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2008-01-31 | — | — | WO | disclosed |
| US-20070287756-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-12-13 | — | — | US | disclosed |
| EP-1764616-A2 | Method for identifying apoptosis modified proteins | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-20070032427-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-02-08 | — | — | US | disclosed |
| US-20050158397-A1 | Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors | HENRY FORD HEALTH SYSTEM | 2005-07-21 | — | — | US | disclosed |
| US-20050129684-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2005-06-16 | — | — | US | disclosed |
| US-20040022779-A1 | Method for identifying apoptosis-modified proteins | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2001039792-A2 | THE USE OF CASPASE 9 INHIBITORS TO TREAT OCULAR NEURAL PATHOLOGY | ALCON UNIVERSAL LTD. (CH) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP3 1797/4885CASP7 1282/4885CASP1 1854/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | CASP3 2377/4885CASP7 1005/4885CASP1 2775/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | CASP3 696/4885CASP7 972/4885CASP1 2041/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CASP3 1797/4885CASP7 1282/4885CASP1 1854/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP3 1797/4885CASP7 1282/4885CASP1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.